Form 4: Intra-Cellular Therapies Director Robert L. Van Nostrand Reports Acquisition of Common Stock
SEC Form 4 Filing
Director Robert L. Van Nostrand of Intra-Cellular Therapies, Inc. reports acquiring 83 shares of common stock at $68.49 per share on June 28, 2024.
Summary
- On June 28, 2024, Robert L. Van Nostrand, a director of Intra-Cellular Therapies, Inc. (ITCI), acquired 83 shares of common stock.
- The acquisition price was $68.49 per share.
- Following the transaction, Van Nostrand directly owns 11,340 shares of ITCI common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track confidence levels and potential alignment of interests between management and shareholders.
Stakeholder Impact
- The transaction provides shareholders with insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 06/28/2024 | Date of the transaction: Robert L. Van Nostrand acquired 83 shares of common stock. |
| 07/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.